Liraglutide vs Eloralintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Victoza, Saxenda
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Also: GSBR-1290, Structure GSBR-1290
A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.
Key Comparison Insights
- Liraglutide is FDA approved, while Eloralintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Liraglutide has stronger research evidence (FDA Approved) compared to Eloralintide (Phase 2 Clinical Trial).
Detailed Comparison
| Attribute | Liraglutide | Eloralintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Liraglutide has 97% homology to native GLP-1 with modifications for extended half-life. It slows gastric emptying, increases insulin secretion, suppresses glucagon, and acts on brain appetite centers to reduce hunger. | Eloralintide is a small-molecule, non-peptide GLP-1 receptor agonist that mimics the action of GLP-1. Unlike traditional peptide-based GLP-1 agonists, it is orally bioavailable without requiring absorption enhancers. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. |
| Common Dosing | 1.8-3 mg daily Once daily | 120-240mg once daily (oral) Once daily |
| Administration | Subcutaneous injection daily | Oral tablet |
| Typical Duration | Long-term / chronic use | 36 weeks in Phase 2 trials |
| Best Time to Take | Morning or evening, consistent daily | - |
Possible Side Effects May vary by individual |
|
|
| Research Summary | SCALE trials showed 5-10% weight loss. LEADER trial demonstrated cardiovascular benefits in diabetics. Extensive long-term safety data available. First GLP-1 approved specifically for weight management (Saxenda). | Phase 2 GSBR-1290-004 trial (2024) showed up to 14.4% body weight reduction at 36 weeks with the highest dose. Results showed a favorable GI tolerability profile compared to injectable GLP-1 agonists, with lower rates of nausea and vomiting. The oral small-molecule design eliminates the need for injections, potentially improving patient adherence. Structure Therapeutics reported positive Phase 2b results with dose-dependent weight loss across multiple cohorts. |
Frequently Asked Questions: Liraglutide vs Eloralintide
What is the difference between Liraglutide and Eloralintide?
Liraglutide is a weight loss peptide that an fda-approved glp-1 receptor agonist for type 2 diabetes and chronic weight management. the predecessor to semaglutide with daily dosing. Eloralintide is a weight loss peptide that a next-generation oral glp-1 receptor agonist developed by structure therapeutics (now ventyx biosciences). shows comparable weight loss to injectable glp-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Liraglutide or Eloralintide?
Neither is universally "better" - the choice depends on your specific goals. Liraglutide is typically used for weight loss purposes, while Eloralintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Liraglutide and Eloralintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Liraglutide and Eloralintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.